Skip to main content
SpringerLink
Log in

Medikamentöse vasoaktive Therapien von Mikrozirkulationsstörungen bei rheumatischen Erkrankungen

  • ÜBERSICHT
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Apras S, Ertanli I, Ozbalkan Z, Kiraz S, Ozturk MA, Haznedaroglu IC, Cobankara V, Pay S, Calguneri M (2003) Effects of oral cyclophosphamide and prednisone therapy on the endothelial function and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 48(8):2256–2261

    Article  CAS  PubMed  Google Scholar 

  2. Andersen GN, Mincheva-Nilsson L, Kazzam E, Nyberg G, Klintland N, Petersson AS, Rantapaa-Dahlqvist S, Waldenstrom A, Caidahl K (2002) Assessment of vascular function in systemic sclerosis: indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production. Arthritis Rheum 46(5):1324–1332

    Google Scholar 

  3. Teh LS, Manning J, Moore T, Tully MP, O’Reilly D, Jayson MI (1995) Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud’s phenomenon. Br J Rheumatol 34(7):636–641

    Google Scholar 

  4. Muir AH, Robb R, McLaren M, Daly F, Belch JJ (2002) The use of Ginkgo biloba in Raynaud’s disease: a double-blind placebo-conbtrolled trial. Vasc Med 7(4):265–267

    Google Scholar 

  5. Kamphuis J, Smits P, Thien T (1994) Vascular effects of pentoxifylline in humans. J Cardiovasc Pharmacol 24(4):648–654

    Google Scholar 

  6. Mollitt DL, Poulos ND (1991) The role of pentoxifylline in endotoxin-induced alterations of red cell deformability and whole blood viscosity in the neonate. J Pediatr Surg 26(5):572–574

    Google Scholar 

  7. Burgmann H, Stauffer F, Hollenstein U, Wiesinger E, Georgopoulos A, Graninger W, Breyer S (1995) Effect of various pentoxiphylline concentrations on macrophage inflammatory protein 1 alpha production. Antimicrob Agents Chemother 39(2):574–575

    Google Scholar 

  8. Neirotti M, Longo F, Molaschi M, Macchione C, Pernigotti L (1987) Functional vascular disorders: treatment with pentoxifylline. Angiology. 38(8):575–580

    Google Scholar 

  9. Garay, I, Csiki Z, Szücs G, Varga J, Galuska L (2003) Visualizing the Effect of Pentoxyphyllin Infusion Therapy on the circulation of the Hand by Tc-99m DPTA Scintigraphy. Clinical Nuclear Medicine 28(7):611–612

    Google Scholar 

  10. Goldberg, J, Diesk A (1986) Successful treatment of Raynaud’s phenomenon with pentoxxifylline. Arthritis Rheum 29(8):1055–1056

    Google Scholar 

  11. Wollersheim H, Thien T, Fennis J, van Elteren P, van’t Laar A (1986) Double-blind, placebo-controlled study of prazosin in Raynaud’s phenomenon. Clin Pharmacol Ther 40(2): 219–225

    Google Scholar 

  12. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A (2000) Prazosin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev (2):CD000956

    Google Scholar 

  13. Sanchez O, Sitbon O, Garcia G, Jais X, Simonneau G, Humbert O (2003) Pulmonary artery hypertension associated with connective tissue diseases. Presse Med 32(17):789–799

    Google Scholar 

  14. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE (2003) Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum 44(8):1841–1847

    Google Scholar 

  15. Meyrick Thomas RH, Rademaker M, Grimes SM, MacKay A, Kovacs IB, Cook ED, Bowcock SM, Kirby JD (1987) Nifedipine in the treatment of Raynaud’s phenomenon in patients with systemic sclerosis. Br J Dermatol. 117(2):237–241

    Google Scholar 

  16. Sturgill MG, Seibold JR (1998) Rational use of calcium-channel antagonists in Raynaud’s phenomenon. Curr Opin Rheumatol 10(6):584–588

    Google Scholar 

  17. Rhedda A, McCans J, Willan AR, Ford PM (1985) A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud’s phenomenon. J Rheumatol 12(4):724–727

    Google Scholar 

  18. Kahan A, Amor B, Menkens CJ (1985) A randomized double-blind trial of diltiazem in the treatment of Raynaud’s phenomenon. Ann Rheum dis 44(1):30–33

    Google Scholar 

  19. Dolan AL, Kassimos D, Gibson T, Kingsley GH (1995) Diltiazem induces remission of calcinosis in scleroderma. Br J Rheumatol 34(6):576–578

    Google Scholar 

  20. Rey RH, Marrero G, Chwojnik A, Martinez JA, Maldonado Cocco J, Rodrigue S, Casabe H (1997) Effect of diltiazem on cold-induced left ventricular dysfunction in patients with systemic sclerosis. Medicina (B Aires) 57(1):47–51

    Google Scholar 

  21. Cattau EL Jr, Castell DO, Johnson DA, Spurling TJ, Hirszel R, Chobanian SJ, Richter JE (1991) Diltiazem therapy for symptoms associated with nutcracker esophagus. Am J Gastroenterol 86(3):272–276

    Google Scholar 

  22. Mazagri R, Shuaib A (1992) Flunarizine is effective in prophylaxis of headache associated with scleroderma. Headache 32(6):298–299

    Google Scholar 

  23. Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr (1990) Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 113(5):352–357

    Google Scholar 

  24. Walker JG, Ahern MJ, Smith MD, Coleman M, Pile K, Rischmueller M, Cleland L, Roberts-Thomson PJ (2003) Intern Med J 33(5–6):216–220

    Google Scholar 

  25. Lin AT, Clements PJ, Furst DE (2003) Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosis. Rheum Dis Clin Noth Am 29(2):409–426

    Google Scholar 

  26. DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, Mayes M, White B, Wigley F, Barr W, Moreland L, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Clements PJ (2002) Predictors and outcomes of scleroderma renal crisis: the high-dose versus lowdose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 46(11):2983–2989

    Google Scholar 

  27. Challenor VF, Waller DG, Hayward RA, Griffin MJ, Roath OS (1991) Subjectve and objective assessment of enalapril in primary Raynaud’s phenomenon. Br J Clin Pharmacol. 31(4):477–480

    Google Scholar 

  28. Janini SD, Scott DG, Coppock JS, Bacon PA, Kendall MJ (1988) Enalapril in Raynaud’s phenomenon. J Clin Pharm Ther 13(2):145–150

    Google Scholar 

  29. Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, Black CM (1999) Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 42(12):2646–2655

    Google Scholar 

  30. Tosi S, Marchesoni A, Messina K, Bellintani C, Sironi G, Faravelli C (1987) Treatment of Raynaud’s phenomenon with captopril. Drugs Exp Clin Res 13(1):37–42

    Google Scholar 

  31. Rustin MH, Almond NE, Beacham JA, Brooks RJ, Jones DP, Cooke ED, Dowd PM (1987) The effect of captopril on cutaneous blood flow in patients with primary Raynaud’s phenomenon. Br J Dermatol. 117(6):751–758

    Google Scholar 

  32. Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, Black CM (2001) Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 40(9):1038–1043

    Google Scholar 

  33. Pope J, Fenlon D, Thompson A et al (2000) Ketanserin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syste Rev2000:CD000954

    Google Scholar 

  34. Varela-Aguilar JM, Sanchez-Roman J, Talegon Melendez A, Castillo Palma MJ (1997) Comparative study of misoprostol and nifedipine in the treatment of Raynaud’s phenomenon secondary to systemic diseases. Hemodynamic assessment with Doppler duplex. Rev Clin Esp 197(2):77–83

    Google Scholar 

  35. Mohrland JS, Porter JM, Smith EA, Belch J, Simms MH (1985) A multiclinic, placebo-controlled, doubleblind study of prostaglandin E1 in Raynaud’s syndrome. Ann Rheum Dis 44(11):754–760

    Google Scholar 

  36. Bartolone S, Trifiletti A, De Nuzzo G, Scamardi R, Larosa D, Sottilotta G, Raffa A, Barbera N (1999) Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic slcerosis and significant Raynaud’s phenomenon. Minerva Cardioangiol 47(5):137–143

    Google Scholar 

  37. Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP (1992) Intravenous iloprost treatment of Raynaud’s phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 19(9):1407–1414

    Google Scholar 

  38. Bali G, Alberer E (2003) Iloprosttherapie bei systemischer Sklerodermie. Hautarzt 54:845–851

    Google Scholar 

  39. Riemekasten G, Jepsen H, Burmester GR, Hiepe F (1998) Iloprost über 21 Tage als wirksame Therapie bei der progressiven systemischen Skelrodermie-Fallbeschreibung und Literaturübersicht. Z Rheumatol 57:118–124

    Article  CAS  PubMed  Google Scholar 

  40. Stratton R, Shiwen X, Martini G, Leask A, Haberberger T, Martin GR, Black CM, Abraham D (2001) Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 108(2):241–250

    Google Scholar 

  41. Della Bella S, Molteni M, Mascagni B, Zulian C, Compasso S, Scorza R (1997) Cytokine production in scleroderma patients: effects of therapy with either iloprost or nifedipine. Clin Exp Rheumatol 15(2):135–141

    Google Scholar 

  42. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A (2000) Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Chochrane Atabase Syst Rev (2):CD000953

    Google Scholar 

  43. Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E, Arpaia G, Sardina M, Origgi L, Vanoli M (2001) Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud’s phenomenon. A randomized, controlled study. Clin Exp Rheum 19(5):503–508

    Google Scholar 

  44. Zulian F, Corona F, Gerloni V, Falcini F, Buoncompagni A, Scarazatti M, Martini G, Zacchello F (2003) Safety and efficacy of iloprost for the treatment of ischemic digits in paediatric connective tissue diseases. Rheumatology, Oxford

  45. Rademaker M, Cooke ED, Almond NE, Beacham JA, Smith RE, Mant TG, Kirby JD (1989) Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud’s phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 298(6673):561–564

    Google Scholar 

  46. Wigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman M, Martin R., Collier DH et al (1998) Oral iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double blind study. Arthritis Rheum 41(4):670–677

    Google Scholar 

  47. Hiida M, Ushiyama O, Suzuki N, Ohta A, Nagasawa K, Yamaguchi M (1996) The effect of beraprost sodium on the Raynaud’s phenomenon Nihon Rinsho Meneki Gakkai Kaishi 19(3):193–200

    Google Scholar 

  48. Kaburaki J, Kuwana M, Akizuki M, Takano M, Tojo T (1995) Efficacy of beraprost sodium on Raynaud’s phenomenon in patients with systemic sclerosis. Nihon Rinsho Meneki Gakkai Kaishi 18(1):29–35

    Google Scholar 

  49. Vayssairat M (1999) Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicenter Group for the Study of Vascular Acrosyndromes. J Rheumatol 26(10):2173–2178

    Google Scholar 

  50. Matsukawa Y, Saito O, Aoki M, Abe M, Nishinarita S, Sawada S, Horie T, Naruse S, Hiranuma M (2002) Long-term administration of beraprost, an oral prostacyclin analogue, improves pulmonary diffusion capacity in patients with systemic sclerosis. Prostaglandins Leukot Essent Fatty Acids 67(1):45–49

    Google Scholar 

  51. Xu SW, Denton CP, Dashwood MR, Abraham DJ, Black CM (1998) Endothelin-1 regulation of intercellular adhesion molecule-1 expression in normal and sclerodermal fibroblasts. J Cardiovasc Pharmacol 31 Suppl 1:S545–547

    Google Scholar 

  52. Xu S, Denton CP, Holmes A, Dashwood MR, Abraham DJ, Black CM (1998) Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol 31 Suppl 1:S360–S363

    Google Scholar 

  53. Kikuchi K, Kadono T, Sato S, Tamaki K, Takehara K (1995) Impaired growth response to endothelin-1 in scleroderma fibroblasts. Biochem Biophys Res Commun 207(2):829–838

    Google Scholar 

  54. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simmoneau G (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346(12):896–903

    Article  CAS  PubMed  Google Scholar 

  55. Shawket S, Dickerson C, Hazleman B, Brown MJ (1991) Prolonged effect of CGRP in Raynaud’s patients: a double-blind randomised comparison with prostacyclin. Br J Clin Pharmacol 32(2):209–213

    Google Scholar 

  56. Denton CP, Howell K, Stratton RJ, Black CM (2000) Long-term low molecular weight heparin therapy for severe Raynaud’s phenomenon: a pilot study. Clin Exp Rheumatol 18(4):499–502

    Google Scholar 

  57. Kohorst WR, Bay WH (1982) Reversal of end-stage kidney failure in two scleroderma patients treated with anticoagulation. Am J Kidney Dis 2(3):347–348

    Google Scholar 

  58. Fritzler MJ, Hart DA (1990) Prolonged improvement of Raynaud’s phenomenon and scleroderma after recombinant tissue plasminogen activator therapy. Arthritis Rheum 33(2):274–276

    Google Scholar 

  59. Paye M, Read D, Nusgens B, Lapiere CM (2003) Factor XIII in scleroderma: in vitro studies. Br J Dermatol 122(3):371–382

    Google Scholar 

  60. Guillevin L, Chouvet B, Mery C, De Gery A, Thivolet J, Godeau P, Delbarre F (1985) Treatment of progressive systemic sclerosis using factor XIII. Pharmatherapeutica 4(2):76–80

    Google Scholar 

  61. Guillevin L, Euller-Ziegler L, Chouvet B, De Gery A, Chassoux G, Lafay P, Ziegler G, Godeau P, Amor B, Thivolet J (1985) Treatment of systemic scleroderma with factor XIII in 86 patients, with long-term follow-up. Presse Med 14(46):2327–2329, French

    Google Scholar 

  62. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H (1994) Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 266:L536–543

    Google Scholar 

  63. Wallis RM, Corbin JD, Francis SH, Ellis P (1999) Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae corneae and aortic rings in vitro. Am J Cardiol 83:3C–12C

    Google Scholar 

  64. Gertner E (2003) Treatment with sildenafil for the healing of refractory skin ulcerations in the antiphospholipid syndrome. Lupus 12:135–135

    Google Scholar 

  65. Lichtenstein JR (2003) Use of sildenafil citrate in Raynaud’s phenomenon: comment on the article by Thompson et al 48:282–283

  66. Rosenkranz S, Diet F, Karasch T, Weihrauch J, Wassermann K, Erdmann E (2003) Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the raynaud phenomenon. Ann Int Med 139:871–873

    Google Scholar 

  67. Rich S (1998) Primary Pulmonary Hypertension: Executive Summary from the World Symposium—Primary Pulmonary Hypertension. http://www.who.int/ncd/cvd/pph.html

  68. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A (2004) Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43:5S–12S

    Article  PubMed  Google Scholar 

  69. Hoeper MM, Galie N, Simonneau G, Rubin LJ (2002) New treatments for pulmonary aterial hypertension. Am J Respir Crit Care Med 165:1209–1216

    Article  PubMed  Google Scholar 

  70. Tuder RM, Groves B, Badesch DB, Voelkel NF (1994) Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144:275–285

    CAS  PubMed  Google Scholar 

  71. Mitani Y, Ueda M, Komatsu R, Maruyama K, Nagai R, Matsumura M, Sakurai M (2001) Vascular smooth muscle cell phenotypes in primary pulmonary hypertension. Eur Respir J 17:316–320

    Google Scholar 

  72. Voelkel NF, Hoeper M, Maloney J, Tuder RM (1996) Vascular endothelial growth factor in pulmonary hypertension. Ann NY Acad Sci 796:186–193

    Google Scholar 

  73. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, Diehl JH, Crow J, Long W (1990) Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 112:485–491

    Google Scholar 

  74. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, et al (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334:296–302

    Article  CAS  PubMed  Google Scholar 

  75. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jobsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TA Jr (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132:425–434

    CAS  PubMed  Google Scholar 

  76. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ (2002) Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165:800–804

    PubMed  Google Scholar 

  77. McLaughlin VV, Gaine SP, Barst RJ, Oudiz RJ, Bourge RC, Frost A, Robbins IM, Tapson VF, McGoon MD, Badesch DB, Sigman J, Roscigno R, Blackburn SD, Arneson C, Rubin LJ, Rich S (2003) Efficacy and safety for treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 41:293–299

    Google Scholar 

  78. Galie N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, Sitbon O, Torbicki A, Delcroix M, Naeije R, Hoeper M, Chaouat A, Morand S, Besse B, Simonneau G (2002) Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39:1496–1502

    Article  CAS  PubMed  Google Scholar 

  79. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, Wasserman K, Oudiz R, Shapiro S, Robbins IM, Channick R, Badesch D, Rayburn BK, Flinchbaugh R, Sigman J, Arneson C, Jeffs R (2003) Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41:2119–2125

    Google Scholar 

  80. Olschewski H, Simonneau G, Galie N, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347:322–329

    Article  CAS  PubMed  Google Scholar 

  81. Higenbottam TW, Butt AY, Dinh-Xaun AT, Takao M, Cremona G, Akamine S (1998) Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart 79:175–179

    Google Scholar 

  82. Channick R, Badesch DB, Tapson VF, Simonneau G, Robbins I, Frost A, Roux S, Rainisio M, Bodin F, Rubin LJ (2001) Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. J Heart Lung Transplant 20:262–263

    Google Scholar 

  83. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896–903

    Article  CAS  PubMed  Google Scholar 

  84. Galie N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, Espinola-Zavaleta N, Rocchi G, Manes A, Frantz R, Kurzyna M, Nagueh SF, Barst R, Channick R, Dujardin K, Kronenberg A, Leconte I, Rainisio M, Rubin L (2003) Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 41:1380–1386

    Google Scholar 

  85. Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J (2002) Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 121:1860–1868

    Google Scholar 

  86. Rubin LJ, Galie N, Badesch BD, et al (2004) Ambrisentan improves exercise capacity and clinical measures in pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med (in press)

  87. Prasad S, Wilkinson J, Gatzoulis MA (2000) Sildenafil in primary pulmonary hypertension. N Engl J Med 343:1342

    CAS  PubMed  Google Scholar 

  88. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M, Sybrecht GW (2001) Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104:1218–1222

    CAS  PubMed  Google Scholar 

  89. Michealakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S (2002) Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105:2398–2403

    Google Scholar 

  90. Abrams D, Schulze-Neick I, Magee AG (2000) Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 84:E4

    Google Scholar 

  91. Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, Seeger W, Grimminger F (2002) Combination theraphy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136:515–522

    CAS  PubMed  Google Scholar 

  92. Sastry BK, Narasimhan C, Reddy NK, Raju BS (2004) Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 43:1149–1153

    Article  CAS  PubMed  Google Scholar 

  93. Watanabe H, Ohashi K, Takeuchi K, Yamashita K, Yokoyama T, Tran QK, Terada H, Ohashi H, Hayashi H (2002) Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 71:398–402

    Google Scholar 

  94. Molina J, Lucero E, Luluaga S, Bellomio V, Spindler A, Berman A (2003) Systemic lupus erythematosus-associated pulmonary hypertension: good outcome following sildenafil therapy. Lupus 12:321–323

    Google Scholar 

  95. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, Weissmann N, Ghofrani S, Enke B, Seeger W, Grimminger F (2003) Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 42:158–164

    Article  CAS  PubMed  Google Scholar 

  96. Cheitlin MD, Hutter AMJ, Brindis RG, Ganz P, Kaul S, Russell ROJ, Zusman RM (1999) Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation 99:168–177

    Google Scholar 

  97. Ghofrani HA, Olschewski H, Seeger W, Grimminger F (2002) Sildenafil for treatment of severe pulmonary hypertension and commencing right-heart failure. Pneumologie 56:665–672

    Google Scholar 

  98. Reffelmann T, Kloner RA (2003) Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation 108:239–244

    Google Scholar 

  99. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick A, Merkel PA, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Black C (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985–3993

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité, Zentrum C6 im Deutschen Netzwerk für Sklerodermie (BMBF), EUSTAR-Zentrum, Schumannstraße 20/21, 10117, Berlin

    G. Riemekasten

  2. Klinische Forschergruppe III, Nikolaus-Fiebiger-Zentrum für Molekulare Medizin, Glückstraße 6, 91054, Erlangen

    H. Schulze-Koops

Authors
  1. G. Riemekasten
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Schulze-Koops
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Riemekasten.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Riemekasten, G., Schulze-Koops, H. Medikamentöse vasoaktive Therapien von Mikrozirkulationsstörungen bei rheumatischen Erkrankungen. Z. Rheumatol. 64, 123–136 (2005). https://doi.org/10.1007/s00393-005-0691-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-005-0691-y

Search

Navigation